Gclc (Glutamate Cysteine Ligase Catalytic Subunit) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| GCLC (Glutamate-Cysteine Ligase Catalytic Subunit) | |
|---|---|
| Protein Name | Glutamate-Cysteine Ligase Catalytic Subunit |
| Gene | GCLC |
| UniProt | P48506 |
| PDB ID | 2DO7, 2GGF |
| Molecular Weight | 73 kDa |
| Localization | Cytosol |
| Protein Family | ATP-grasp fold family |
GCLC (Glutamate-Cysteine Ligase Catalytic Subunit) is the catalytic subunit of glutamate-cysteine ligase (GCL), the rate-limiting enzyme in glutathione biosynthesis. GCLC contains the active site and catalytic activity, while GCLM (modifier subunit) regulates its function.
GCLC:
GCLC:
Parkinson's Disease: GCLC expression is reduced in substantia nigra of PD patients.
Alzheimer's Disease: GCLC may be affected in AD brain.
ALS: Altered GCLC expression in ALS.
The study of Gclc (Glutamate Cysteine Ligase Catalytic Subunit) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.